

## References

---

Aguilar J.C., Lobiaina Y., Muzio V., Garcia D., Penton E., Iglesias E., Pichardo D., Urquiza D., Rodriguez D., Silva D., Petrovsky N., Guillen G., “Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen,” *Immunol. Cell Biol.*, **82**(2004)539-546.

Akagi T. and Akashi M., “Development of polymeric nanoparticles-based vaccine,” *Nippon Rinsho*, **64**(2006)279-285.

Akagi T., Baba M., Akashi M., Biodegradable nanoparticles as vaccine adjuvants and delivery systems: regulation of immune responses by nanoparticle-based vaccine, *Polymers in nanomedicine*, 11th edition, Berlin: Springer-Verlag Berlin, 2011, 28-30.

Akarca S.U.S. and Lok A.S.F., “Naturally occurring hepatitis B virus core gene mutations,” *Hepatology*, **22**(1995)50-60.

Akira S., Uematsu S., Takeuchi O., “Pathogen recognition and innate immunity,” *Cell*, **124**(2006)783-801.

Alexander P. and Volker B., “Functional surfaces of the hepatitis B virus capsid,” *J Virol.*, (22),**83**(2009)11616-11623.

Ando K., Guidotti L.G., Wirth S., Ishikawa T., Missale G., Moriyama T., Schreiber T.D., Schlicht H.J., Huang S.N., Chisari F.V., “Class I-restricted cytotoxic T lymphocytes are directly cytopathic for their target cells in vivo,” *J Immunol.*, **152**(1994)3245–3253.

Ando Y., Yasuoka C., Mishima T., Ikematsu T., Uede T., Matsunaga T., Inobe M., “Concanavalin A-mediated T cell proliferation is regulated by herpes virus entry mediator co-stimulatory molecule,” *In Vitro Cell Dev. Biol. Anim.*, (4),**50**(2014)313-320.

Asadi A., Huat B.B.K., Nahazanan H., Keykhah H.A., “Theory of Electro osmosis in Soil,” *Int. J Electrochem. Sci.*, **8**(2013)1016-1025.

Asabe S., Wieland S.F., Chattopadhyay P.K., Roederer M., Engle R.E., Purcell R.H., Chisari F.V., “The size of the viral inoculum contributes to the outcome of hepatitis B virus infection,” *J Virol.*, **83**(2009)9652-9662.

Babensee J.E., “Interaction of dendritic cells with biomaterials,” *Semin. Immunol.*, **20**(2007)101–108.

Bai H., Zhang L., Ma L., Dou X.G., Feng G.H., Zhao G.Z., “Relationship of hepatitis B virus infection of placental barrier and hepatitis B virus intra-uterine transmission mechanism,” *World J Gastroenterol.*, (26),**13**(2007)3625-3630.

Bakand S. and Hayes A., “Toxicological considerations, toxicity assessment, and risk management of inhaled nanoparticles,” *Int. J Mol. Sci.*, (6),**17**(2016)929-935.

Bal S.M., Slutter B., van Riet E., Kruithof A.C., Ding Z., Kersten G.F., Jiskoot W., Bouwstra J.A., “Efficient induction of immune responses through intradermal vaccination with N-trimethyl chitosan containing antigen formulations,” *J Controlled Release*, **142**(2010)374-383.

Banatvala J., Van Damme P., Oehen S., “Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory,” *Vaccine*, (7),**19**(2000)877-885.

Banchereau J. and Steinman R.M., “Dendritic cells and the control of immunity,” *Nature*, **392**(1998)245-252.

Barker L.F., Chisari F.V., McGrath P.P., Dalgard D.W., Kirschstein R.L., Almeida L.D., Edington T.S., Sharp D.G., Peterson M.R., “Transmission of type B viral hepatitis to chimpanzees” *J Infect Dis.*, **127**(1973)648-662.

- Barton G.M. and Kagan J.C., “A cell biological view of Toll-like receptor function: regulation through compartmentalization,” *Nat. Rev. Immunol.*, **9**(2009)535-542.
- Beck J. and Nassal M., “Hepatitis B virus replication,” *World J Gastroenterol.*, (1),**13**(2007)48-64.
- Begovich A.B., Moonsamy P.V., Mack S.J., Barcellos L.F., Steiner L.L, Grams S., Suraj-Baker V., Hollenbach J., Trachtenberg E., Louie L., Zimmerman P., Hill A.V., Stoneking M., Sasazuki T, Kononkov V.I., Sartakova M.L., Titanji V.P., Rickards O., Klitz W., “Genetic variability and linkage disequilibrium within the HLA-DP region: analysis of 15 different populations,” *Tissue Antigens*, (5),**57**(2001)424-439.
- Bertoletti A., Ferrari C., Fiaccadori F., Penna A., Margolskee R., Schlicht H.J., Fowler P., Guilhot S., Chisari F.V., “HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen,” *Proc. Natl. Acad. Sci.*, **88**(1991)10445–10449.
- Bertolino P., Bowen D.G., McCaughan G.W., Fazekas de St. Groth B., “Antigen-specific primary activation of CD8<sup>+</sup> T cells within the liver,” *J Immunol.*, (9),**166**(2001)5430-5438.
- Bhavsar M.D. and Aniji M.M., “Polymeric nano and micro particle technologies for oral gene delivery,” *Expert Opin Drug Del.*, **4**(2007)197-213.
- Biddeberg F., Schimmer B.B., Spahn D.R., “Transfusion-transmissible infections and transfusion-related immunomodulation,” *Best Pract. Res. Clin. Anesthesiol.*, (3),**22**(2008)503-517.
- Black M., Trent A., Tirrell M., Olive C., “Advances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonists,” *Expert Rev Vaccines*, **9**(2010)157–173.

Bocher W.O., Galun E., Marcus H., Daudi N., Terkieltaub D., Shouval D., Lohr H.F., Reisner Y., “Reduced hepatitis B virus surface antigen-specific Th1 helper cell frequency of chronic HBV carriers is associated with a failure to produce antigen-specific antibodies in the trimera mouse,” *Hepatology*, (2), **31**(2000)847-853.

Bocher W.O., Marcus H., Shakarchy R., Dekel B., Shouval D., Galun E., Reisner Y., “Antigen-specific B and T cells in human/mouse radiation chimera following immunization in vivo,” *Immunology*, **96**(1999)634-641.

Borzi R.M., Dal Monte P., Honorati M.C., Facchini A., “IgG subclass distribution of anti-HBs antibodies following vaccination with cDNA HBsAg,” *J Immunol. Methods*, (1), **146**(1992)17-23.

Boussif O., Lezoualch O., Zanta M.A., Mergny M.D., Scherman D., Demeneix B., Behr J.P., “A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo,” *Proc. Natl. Acad. Sci. USA*, **92**(1995)7297-7301.

Bowen D.G., Zen M., Holz L., Davis T., McCaughan G.W., Bertolino P., “The site of primary T cell activation is a determinant of the balance between intrahepatic tolerance and immunity,” *J Clin. Invest.*, (5), **114**(2004)701-712.

Box G.E.P. and Wilson K.B., “On the experimental attainment of optimum conditions,” *J R. Stat. Soc. Ser.*, **13**(1951)1-45.

Brayden D.J., Cryan S.A., Dawson K.A., Brien P.J.O., Simpson J.C., “High-content analysis for drug delivery and nanoparticle applications,” *Drug Dis. Today*, (8), **20**(2015) 942-957.

Brewer J.M., “(How) do aluminium adjuvants work?,” *Immunol. Lett.*, (1), **102**(2005)10–15.

Budhian A., Siegel S.J., Winey K.I., “Haloperidol-loaded PLGA nanoparticles: systematic study of particle size and drug content,” *Int. J Pharm.*, **336**(2007)367-375.

Cavanaugh V.J., Guidotti L.G., Chisari F.V., “Inhibition of hepatitis B virus replication during adenovirus and cytomegalovirus infections in transgenic mice,” *J Virol.*, **72**(1998)2630–2637.

Chen D.S., “Toward elimination and eradication of hepatitis B,” *J Gastroenterol. Hepatol.*, **25**(2010)19-25.

Chen J., Liu M.K., Zhang W., Li Y., Zhou X., Bai L., Yuan Z., “New insights into hepatitis B virus biology and implications for novel antiviral strategies,” *Nat. Sci. Rev.*, **2**(2015)296-313.

Chen R., Yue Z., Eccleston M.E., Williams S., Slater N.K., “Modulation of cell membrane disruption by pH responsive pseudo-peptides through grafting with hydrophilic side chains,” *J Controlled Release*, **108**(2005)63-72.

Chien R.N. and Liaw Y.E., “Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success,” *Best Pract. Res. Clin. Gastroenterol.*, (6),**22**(2008)1081-1092.

Chisari F.V., Isogawa M., Wieland S.F., “Pathogenesis of hepatitis B virus infection,” *Pathol. Biol. (Paris)*, **58**(2010)58:258-266.

Chopra S., Motwani S.K., Iqbal Z., Talegaonkar S., Ahmad F.J, Khar R.K., “Optimization of polyherbal gels for vaginal drug delivery by box-behnen statistical design,” *Eur. J Pharm. Biopharm.*, **67**(2007)120-131.

Chu P. and Sadullah S., “The current role of amphotericin B lipid complex in managing systemic fungal infections,” *Curr. Med. Res. Opin.*, **25**(2009)3011-3020.

Cleland J.L. and Jones A.J.S., “Stable formulations of recombinant human growth hormone and interferon-gamma for microencapsulation in biodegradable microspheres,” *Pharm. Res.*, **13**(1996)1464-1475.

Coffman R.L., "Origins of the T(H)1-T(H)2 model: a personal perspective," *Nat. Immunol.*, **7**(2006)539-541.

Correia-Pinto J.F., Csaba N., Alonso M.J., "Vaccine delivery carriers: insights and future perspectives," *Int. J Pharm.*, **440**(2013)27-38.

Couvreur P. and Vauthier C., "Nanotechnology: intelligent design to treat complex disease," *Pharm. Res.*, **23**(2006)1417-1450.

Dandri M., Volz T.K., Lutgehetmann M., Petersen J., "Animal models for the study of HBV replication and its variants," *J Clin. Virol.*, **34**(2005)54-62.

Danhier F., Ansorena E., Silva J.M., Coco R., Le Breton A., Pr at V., "PLGA-based nanoparticles: an overview of biomedical applications," *J Controlled Release*, **161**(2012)505-522.

Danhier F., Feron O., Preat V., "To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery," *J. Controlled Release*, **148**(2010)135-146.

Das A., and Maini M.K., "Innate and adaptive immune responses in hepatitis B virus infection," *Immunol. Liver Dis.*, **28**(2010)126-132.

Davis C.L., Gretch D.R., Carithers R.L., "Hepatitis B and transplantation," *Infect Dis. Clin. North Am.*, **9**(1995)925-941.

Debin A., Kravtsoff R., Santiago J.V., Cazales L., Sperandio S., Melber K., "Intranasal immunization with recombinant antigens associated with new cationic particles induces strong mucosal as well as systemic antibody and CTL responses," *Vaccine*, **20**(2002)2752-2763.

Degli E.S. and Shah D., "Hepatitis B in pregnancy: challenges and treatment," *Gastroenterol. Clin. North Am.*, (2),**40**(2011)355-372.

- Demirel M. and Kayan B., “Application of response surface methodology and central composite design for the optimization of textile dye degradation by wet air oxidation,” *Int. J Industrial Chem.*, **3**(2012)24.
- De M.S., Depla E., Maertens G., Soumillion A., Yap S.H., “Characterization of small hepatitis B surface antigen epitopes involved in binding to human annexin,” *J Viral Hepat.*, (4),**6**(1999)277-285.
- Di Bisceglie A.M., “Combination therapy for hepatitis B,” *Gut*, **50**(2002)443-445.
- Dion S., Bourguine M., Godon O., Levillayer F., Michel M.L., “Adenoassociated virus-mediated gene transfer leads to persistent hepatitis B virus replication in mice expressing HLA-A2 and HLADR1 molecules,” *J Virol.*, **87**(2013) 5554-5563.
- Djupesland P.G., Skretting A., Winderen M., Holand T., “Breath actuated device improves delivery to target sites beyond the nasal valve,” *Laryngo.*, **116**(2006)466-472.
- Dong C., “TH17 cells in development: an updated view of their molecular identity and genetic programming,” *Nat. Rev. Immunol.*, **8**(2008)337-348.
- Duran-Struuck R. and Dysko R.C., “Principles of bone marrow transplantation (BMT): providing optimal veterinary and husbandry care to irradiated mice in BMT studies,” *J Am. Assoc. Lab Anim. Sci.*, **48**(2009)11–22.
- Duque G.A. and Descoteaux A., “Macrophage Cytokines: Involvement in Immunity and Infectious Diseases,” *Front Immunol.*, **5**(2014)491-498.
- Dusheiko G.M., Hoofnagle J.H., Cooksley W.G., James S.P., Jones E.A., “Synthesis of antibodies to hepatitis B virus by cultured lymphocytes from chronic hepatitis B surface antigen carriers,” *J Clin. Invest.*, **71**(1983)1104-1113.

Dutka M., Ditaranto M., Løvås T., “Application of a Central Composite Design for the Study of NO<sub>x</sub> Emission Performance of a Low NO<sub>x</sub> Burner,” *Energies*, **8**(2015)3606-3627.

Eren R., Lubin I., Terkieltab D., Ben-Moshe O., Zauberman A., Uhlmann R., Tzahor T., Moss S., Ilan E., Shouval D., Galun E., Daudi N., Marcus H., Reisner Y., Dagan S., “Human monoclonal antibodies specific to hepatitis B virus generated in a human/mouse radiation chimera: the trimera system,” *Immunol*, (2),**93**(1998)154-161.

Fagarasan S. and Honjo T., "Intestinal IgA Synthesis: Regulation of front-line body defenses," *Nat. Rev. Immunol.*, (1),**3**(2003)63–72.

Fairley C.K. and Read T.R., “Vaccination against sexually transmitted infections,” *Curr. Opin Infect Dis.*, (1),**66**(2012)66-72.

Feliu N., Mikhail J., Zyuzin V., Ashraf S., Valdeperez D., Masood A., Said A.H., Escudero A., Pelaz B., Gonzalez E., Duarte M.A.C., Roy S., Chakraborty I., Lim M.L., Sjoqvist S., Jungebluth P., Parak W.J., “Quantitative uptake of colloidal particles by cell cultures,” *Total Environment*, (568),**15**(2016)819-828.

Fifi S.T., Gamvrellis A., Crimeen-Inwin B., Pietersz G.A., Li J., Mottram P.L., McKenzie I.F.C., Plebanski M., “Size-dependent Immunogenicity: therapeutic and protective properties of nanovaccines against tumors,” *J Immunol.*, **173**(2004)3148-3154.

Foged C., Brodin B., Frokjaer S., Sundblad A., “Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model,” *Int. J Pharm.*, **298**(2005)315–322.

Francois G., Kew M., Van Damme P., Mphahlele M.J., Meheus A., “Mutant hepatitis B viruses: a matter of academic interest only or a problem with far-reaching implications,” *Vaccine*, (28),**19**(2001)3799-3815.



Freund J., “The mode of action of immunologic adjuvants,” *Adv. Tuberc. Res.*, **7**(1956)130–148.

Frohlich E., “The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles” *Int. J Nanomedicine*, **7**(2012)5577–5591.

Galindo-Rodriguez S., Allémann E., Fessi H., Doelker E., “Physicochemical parameters associated with nanoparticle formation in the salting-out, emulsification-diffusion, and nano-precipitation methods, *Pharm. Res.*, **21**(2004)1428-1439.

Gavilanes F. and Gonzales-Ros A., “Peterson D. Structure of hepatitis B surface antigen: characterization of the lipid components and their association with the viral proteins,” *J Biol. Chem.*, **257**(1982)7770-7777.

Gengoux C. and Leclerc C., “In vivo induction of CD4 + T cell responses by antigen covalently linked to synthetic micro-spheres does not require adjuvant,” *Int. Immunol.* **7**(1995)45-53.

Gentile I. and Borgia G., “Vertical transmission of hepatitis B virus: challenges and solutions,” *Int. J Womens. Health*, **6**(2014)605–611.

Gerberding J.L., “Incidence and prevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus and cytomegalovirus among health care personnel at risk for blood exposure final report from a longitudinal study” *J Infect. Dis.*, (6),**170**(1994)1410-1417.

Gerlich W. and Robinson W.S., “Hepatitis B virus contains protein attached to the 5' end of its complete strand,” *Cell*, **21**(1980)801-811.

Gitlin N., “Hepatitis B: diagnosis, prevention, and treatment,” *Clin. Chemistry*, (8),**43**(1997)1500-1506.

Glebe D. and Urban S., “Viral and cellular determinants involved in hepadna viral entry,” *World J Gastroenterol.*, (1),**13**(2007)22-38.

Gray D., Siepmann K., Van Essen D., Poudrier J., Wykes M., Jainandunsing S., Berghorsdottir S., Dullforce P., “B-T lymphocyte interactions in the generation and survival of memory cells,” *Immunol. Rev.*, **150**(1996)45-61.

Guidotti L.G., Ando K., Hobbs M.V., Ishikawa T., Runkel L., Schreiber R.D., Chisari F.V., “Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice,” *Proc. Natl. Acad. Sci.*, **91**(1994)3764–3768.

Guidotti L.G. and Chisari F.V., “Noncytolytic control of viral infections by the innate and adaptive immune response,” *Annu. Rev. Immunol.*, **19**(2001)65-91.

Guidotti L.G., Ishikawa T., Hobbs M.V., Matzke B., Schreiber R., Chisari F.V., “Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes,” *Immunity*, **4**(1996)25–36.

Guidotti L.G., Matzke B., Schaller H., Chisari F.V., “High-level hepatitis B virus replication in transgenic mice,” *J Virol.*, **69**(1995)6158-6169.

Guidotti L.G., Rochford R., Chung J., Shapiro M., Purcell R., Chisari F.V., “Viral clearance without destruction of infected cells during acute HBV infection,” *Science*, **284**(1999)825–829.

Harding C.V. and Song R., “Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules,” *J Immunol*, **153**(1994)4925-4933.

Heath W.R. and Carbone F.R., “Cross-presentation in viral immunity and self-tolerance,” *Nat. Rev. Immunol.*,**1**(2001)126-134.

Hida S., Miura N.N, Adachi Y., Ohno N., “Effect of *Candida albicans* cell wall glucan as adjuvant for induction of autoimmune arthritis in mice,” *J Autoimmunity*, **25**(2005)93–101.

Hida S., Nagi-Miura N., Adachi Y., Ohno N., “ $\beta$ - Glucan derived from zymosan acts as an adjuvant for collagen-induced arthritis,” *Microbiol. Immunol.*, **50**(2006)453–461.

Hilleman M.R., “Overview of the pathogenesis, prophylaxis and therapeutics of viral hepatitis B, with focus on reduction to practical applications,” *Vaccine*, **19**(2001)1837-1848.

Hoofnagle J.H. and Di Bisceglie A.M., “Serologic diagnosis of acute and chronic viral hepatitis,” *Sem. Liver Dis.*, **11**(1991)73-83.

Hoofnagle J., Shafritz D., Popper H., “Chronic type B hepatitis and the ‘healthy’ HBsAg carrier state,” *Hepatology*, **7**(1987)758-763.

Hosel M., Quasdorff M., Wiegmann K., Webb D., Zedler U., Broxtermann M., Tedjokusumo R., Esser K., Arzberger S., Kirschning C.J., Langenkamp A., Falk C., Buning H., Rose-John S., Protzer U., “Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection,” *Hepatology*, **50**(2009)1773-1782.

Huang L.R., Wu H.L., Chen P.J., Chen D.S., “An immune competent mouse model for the tolerance of human chronic hepatitis B virus infection,” *Proc. Natl. Acad. Sci. USA*, **103**(2006)17862-17867.

Hughes R.A., “Drug injectors and the cleaning of needles and syringes,” *Eur. Addict Res.*, (1), **6**(2000)20-30.

Hung L.M., Su M.J., Chen J.K., “Resveratrol protects myocardial ischemia-reperfusion injury through both NO-dependent and NO-independent mechanisms,” *Free Rad., Biol. Med.*, **36**(2004)774-781.

Illum L., Khan M.A., Mak E., Davis S.S., “Evaluation of carrier capacity and release characteristics for poly( butyl 2-cyanoacrylate) nanoparticles,” *Int. J Pharm.*, **30**(1986)17-28.

Iqbal M., Lin W., Jabbal-Gill I., Davis S.S., Steward M.W., Illum L., “Nasal delivery of chitosan-DNA plasmid expressing epitopes of respiratory syncytial virus (RSV) induces protective CTL response in BALB/c mice,” *Vaccine*, **21**(2003)1478-1485.

Irvine D.J., Hanson M.C., Rakhra K., Tokatlian T., “Synthetic Nanoparticles for Vaccines and Immunotherapy,” *Chem. Rev.*, (19),**115**(2015)11109-11146.

Iwasaki A. and Medzhitov R., “Toll-like receptor control of the adaptive immune responses,” *Nat. Immunol.*, **5**(2004)987-995.

Jaganathan K.S. and Vyas S.P., “Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant Hepatitis B antigen administered intranasally,” *Vaccine*, **24**(2006)4201-4211.

James H.S. and Ellen G.S., *Viruses and Human Disease*. 6th edition Academic Press, San Diego, California, 2002,383-385.

Janeway C.A. and Medzhitov R., “Innate immune recognition,” *Annu. Rev. Immunol.* **20**(2002)197-216.

Janeway C., Travers P., Walport M., Shlomchik M., *Immunobiology: The Immune System in Health and Disease*, 6th edition, Garland Science Publishing: New York, 2005,69-71.

Jensen P.E., “Recent advances in antigen processing and presentation.” *Nat. Immunol.*, **8**(2007)1041-1048.

Jha S., Ramadori F., Quarta S., Biasiolo A., Fabris E., Baldan P., Guarino G., Ruvoletto M., Villano G., Turato C., Gatta A., Mancin F., Pontisso P., Scrimin P.,

“Binding and uptake into human hepatocellular carcinoma cells of peptide-functionalized gold nanoparticles,” *Bioconjugate Chem.*, (1), **28**(2017)222–229.

Kakimi K., Guidotti L.G., Koezuka Y., Chisari F.V., “Natural Killer T Cell Activation Inhibits Hepatitis B Virus Replication in Vivo,” *J. Exp. Med.*, **192**(2000)921–930.

Kalkanidis M., Pietersz G.A., Xiang S.D., Mottram P.L., Crimeen-Irwin B., Ardipradja K., Plebanski M., “Methods for nano-particle based vaccine formulation and evaluation of their immunogenicity,” *Methods*, **40**(2006)20-29.

Kanchan V. and Panda A.K., “Interactions of antigen-loaded poly lactide particles with macrophages and their correlation with the immune response,” *Biomaterials*, **28**(2007)5344–5357.

Kawano Y., and Noma T., “Role of interleukin-2 and interferon-gamma in inducing production of IgG subclasses in lymphocytes of human new borns,” *Immunology*, **88**(1996)40-48.

Kawano Y., Noma T., Yata J., “Regulation of human IgG subclass production by cytokines. IFN-gamma and IL-6 act antagonistically in the induction of human IgG1 but additively in the induction of IgG2,” *J Immunol.*, **153**(1994)4948-4958.

Kendall M., “Engineering of needle-free physical methods to target epidermal cells for DNA vaccination,” *Vaccines*, **24**(2006)4651-4656.

Kersten G., Hirshberg H., “Antigen delivery systems,” *Expert Rev. Vaccines*, **3**(2004)453-462.

Khalil I.A., Kogure K., Akita H., Harashima H., “Uptake pathways and subsequent intracellular trafficking in non-viral gene delivery,” *Pharmacol. Rev.*, **58**(2006)32-45.

Kitani A., Strober W., “Regulation of C gamma subclass germ-line transcripts in human peripheral blood B cells,” *J Immunol.*, **151**(1993)3478- 3488.

Klingmuller U. and Schaller H., "Hepadnavirus infection requires interaction between the viral pre-S domain and a specific hepatocellular receptor," *J Virol.*, (12),**67**(1993)7414-7422.

Kollipara S., Bende G., Movva S., Saha R., "Application of rotatable central composite design in the preparation and optimization of poly(lactic-co-glycolic acid) nanoparticles for controlled delivery of paclitaxel," *Drug Dev. Ind. Pharm.*, (11),**36**(2010)1377-1387.

Krugman S., Overby L.R., Mushahwar I.K., Ling C.M., Frösner G.G., Deinhardt F., "Viral hepatitis, type B: studies on natural history and prevention re-examined," *N Engl. J Med.*, **300**(1979)101-106.

Kumari A., Yadav S.K., Yadav S.C., "Biodegradable polymeric nanoparticles based drug delivery systems," *Colloid Surface B*, **75**(2010)1-18.

Lango A. and Lindblom B., "HLA DQA-DQB haplotypes in a Swedish population," *Eur. J Immunogenet*, (6),**20**(1993)453-460.

Lemon S.M. and Thomas D.L., "Vaccines to prevent viral hepatitis," *N. Engl. J Med.*, (3),**336**(1997)196-204.

Leoni L. and Desai T.A., "Micromachined biocapsules for cell-based sensing and delivery," *Adv. Drug Deliv. Rev.*, **56**(2004)211-229.

Liang S., Du J., Yan H., Zhou Q., Zhou Y., Yuan Z., Yan S., Fu Q., Wang X., Jia S., Peng J., Zhang Y., Zhan L., "A mouse model for studying the clearance of hepatitis B virus in-vivo using a luciferase reporter," *Plos one*, (4),**8**(2013)495-500.

Liang T.J., "Hepatitis B: the virus and disease," *Hepatology*, (5),**49**(2010)13-21.

Li L., Mak K.Y., Shi J., Leung C.H., Wong C.M., Leung C.W., Mak C.S.K., Chan K.Y., Chan N.N.M., Wu E.X., Pong P.W.T., "Sterilization on dextran-coated iron oxide

nanoparticles: Effects of autoclaving, filtration, UV irradiation, and ethanol treatment,” *Microelectro. Eng.*, **111**(2013)310-313.

Lindh M., Uhnöo I., Blackberg J., Duberg A.S., Friman S., Fischler B., Karlström O., Norkrans G., Reichard G., Sangfeldt P., Söderström A., Sönnnerborg A., Weiland O., Wejstål R., Wiström J., “Treatment of chronic hepatitis B infection: an update of Swedish recommendations,” *Scand. J Infect Dis.*, (6),**40**(2008)436-450.

Liu Z.H., Jiao Y.P., Wang Y.F., Zhou C.R., Zhang Z.Y., “Polysaccharides-based nanoparticles as drug delivery systems,” *Adv. Drug Deliv. Rev.*, **60**(2008)1650-1662.

Lodish H., Berk A., Zipursky S.L., Matsudaira P., Baltimore D., Darnell J., *Molecular Cell Biology*, 4th edition, New York: W. H. Freeman; 2000,152-154.

Louis J.A. and Lambert P.H., “Lipopolysaccharides: from immune stimulation to autoimmunity” *Immunopathology*, **2**(1979)15–228.

Maini M.K., Boni C., Lee C.K., Larrubia J.R., Reignat S., Ogg G.S., King A.S., Herberg J., Gilson R., Alisa A., Williams R., Vergani D., Naoumov N.V., Ferrari C., Bertoletti A., “The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection,” *J Exp. Med.*, **191**(2000)1269-1280.

Mäger I., Eiríksdóttir E., Langel K., Andaloussi S., Langel U., “Assessing the uptake kinetics and internalization mechanisms of cell-penetrating peptides using a quenched fluorescence assay,” *Biochimica. Biophysica. Acta*, **1798**(2010)338-343.

Mamo T. and Poland G.A., “Nanovaccinology: the next generation of vaccines meets 21st century materials science and engineering,” *Vaccine*, **30**(2012)6609-6611.

Marcus H., David M., Canaan A., Kulova L., Lubin I., Segall H., Denes L., Erlich P., Galun E., Gan J., Laster M., Reisner Y., “Human/mouse radiation chimera are capable of mounting a human primary humoral response,” *Blood*, **86**(1995)398-406.

Moriyama T., Guilhot S., Klopchin K., Moss B., Pinkert C.A., Palmiter R.D., Brinster R.L., Kanagawa O., Chisari F.V., “Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice,” *Science*, **248**(1990)361–364.

Maruyama T., McLachlan A., Iino S., Koike K., Kurokawa K., Milich D.R., “The serology of chronic hepatitis B infection revisited,” *J Clin. Invest.*, **91**(1993)2586-2595.

Marroccol C., Rinalducci S., Mohamadkhani A., Maria D’Amici G., Zolla L., “Plasma gelsolin protein: a candidate biomarker for hepatitis B-associated liver cirrhosis identified by proteomic approach,” *Blood Transfus.*, (3),**8**(2010)105-112.

Mayer A., Vadon M., Rinner B., Novak A., Wintersteiger R., Frohlich E., “The role of nanoparticle size in hemocompatibility,” *Toxicology*, (2),**258**(2009)139-147.

McAleer W.J., Buynak E.B., Maigetter R.Z., Wampler D.E., Miller W.J., Hilleman M.R., “Human hepatitis B vaccine from recombinant yeast,” *Nature*, (5947),**307**(1984)1781-1780.

McMahon B.J., Alward W.L., Hall D.B., Heyward W.L., Bender T.R., Francis D.P., Maynard P.E., “Acute hepatitis B virus infection: relation of age to clinical expression of disease and subsequent development of the carrier state,” *J Infect Dis.*, **151**(1985)599–603.

Milich D.R. and Leroux-Roels G.G., “Immunogenetics of the response to HBsAg vaccination,” *Autoimmun. Rev.*, (5),**2**(2003)248-257.

Mishra D., Dubey V., Asthana A., Saraf D.K., Jain N.K., “Elastic liposomes mediated transcutaneous immunization against hepatitis B,” *Vaccine*, **24**(2006)4847-4855.

Mishra H., Mishra D., Mishra P.K., Nahara M., Dubey V., Jain N.K., “Evaluation of Solid Lipid Nanoparticles as Carriers for Delivery of Hepatitis B Surface Antigen for Vaccination Using Subcutaneous Route,” *J Pharm Pharmaceut. Sci.*, (4),**13**(2010)495-509.



Moghimi S.M., Hunter A.C., Murray J.C., “Long-circulating and target-specific nanoparticles: theory to practice,” *Pharmacol. Rev.*, **53**(2001)283-318.

Mueller D.L., “Mechanisms maintaining peripheral tolerance,” *Nat. Immunol.*, **11**(2010)21-27.

Mujtaba A., Ali M., Kohli K., “Formulation of extended release cefpodoxime proxetil chitosan alginate beads using quality by design approaches,” *Int. J Biol. Macromol.*, **69**(2014)420-429.

Mulcahy L.A., Pink R C., Carter D.R.F., “Routes and mechanisms of extracellular vesicle uptake,” *J Extra cell Vesicles*, 3(2014)1-14.

Murphy K., Janeway’s Immunology. 8th edition, New York, NY: Garland Science. 2012,423-425.

Murthy N., Xu M., Schuck S., Kunisawa J., Shastri N., Frechet M.J., “A macromolecular delivery vehicle for protein-based vaccines: Acid-degradable protein-loaded microgels,” *Proc. Natl. Acad. Sci. USA*, **29**(2003)4995-5000.

Myers R.H. and Montgomery D.C., Response surface methodology: Process and product optimization using designed experiments, 6th edition New York: Wiley, 2009,89-91.

Myers R.H. and Montgomery D., Response surface methodology: process and product optimization using designed experiments, 8th edition, New York: Wiley, 2002,1-17.

Nadedkar T. D., “Nanovaccines: recent developments in vaccination,” *J. Biosci.*, (6),**34**(2009)995-1003.

Nanda K.S. and Holmdahl R., “Antibody induced arthritis: disease mechanisms and genes involved at the effector phase of arthritis,” *Arthritis Res. Ther.*, **8**(2006)223-226.

Naoumov N.V., Schneider R., Grotzinger T., Jung M.C., Miska S., Pape G.R., Will H., “Precore mutant hepatitis B virus infection and liver disease,” *Gastroenterology*, **102**(1992)538-543.

Nel A.E., Madler L., Velegol D., Xia T., Hoek E.M., Somasundaran P., Klaessig F., Castranova V., Thompson M., “Understanding bio-physicochemical interactions at the nano bio interface,” *Nat. Mater.*, (7),**8**(2009)543–557.

Nellore R.V., Pande P.G., Young D., Bhagat H.R., “Evaluation of biodegradable microspheres as vaccine adjuvant for hepatitis B surface antigen,” *J Parent. Sci. Technol.*, **46**(1992)176-181.

Nobs L., Buchegger F., Gurny R., Allemann E., “Current methods for attaching targeting ligands to liposomes and nanoparticles,” *J Pharm. Sci.*, **93**(2004)1980-1992

Norman G., “Hepatitis B: diagnosis, prevention, and treatment,” *Clin. Chem.*, (8),**48**(1997)1500-1506.

O’Hagan D.T., “Recent advances in immunological adjuvants: the development of particulate antigen delivery systems,” *Exp. Opin. Invest. Drugs*, **7**(1998)349–359.

Ortiz-Interian C.J., Medina M.D., Perez G.O., Bourgoignie J.J., Watkins F., Velez-Robinson E., Schiff E., “Recurrence and clearance of hepatitis B surface antigenemia in a dialysis patient infected with the human immunodeficiency virus,” *Am. J Kidney Dis.*, **16**(1990)154–156.

Pankhurst Q.A., Connolly J., Jones S.K., Dobson J., “Applications of magnetic nanoparticles in biomedicine,” *J Phys D: Applied Phys.*, **36**(2003)167-181.

Panyam J., Zhou W.Z., Prabha S., Sahoo S.K., Labhasetwar V., “Rapid endo-lysosomal escape of poly(dl-lactide-coglycolide) nanoparticles: implications for drug and gene delivery,” *FASEB Journal*, **16**(2002)1217-1226.

- Patel A.R., Kulkarni S.P., Nandedkar T.D., Vavia P.R., "Evaluation of alkyl polyglucoside (based on C10 fatty alcohol) as alternative surfactant in the preparation of peptide loaded nanoparticles," *J Microencap.*, **25**(2008)531-540.
- Patterson L.J., Aberdeen A., Kone J., Haben M., Raymond M., Berkower I., "Formation of HIV-1 Envelope-Hepatitis B Core Antigen Hybrids with High Affinity for CD4," *Biochem. Biophys. Res. Communications*, **285**(2001)639-643.
- Pawar D., Goyal A.K., Mangal S., Mishra N., Vaidya B., Tiwari S., Jain A.K., Vyas S.P., "Evaluation of Mucoadhesive PLGA Microparticles for Nasal Immunization," *The AAPS Journal*, (2),**12**(2010)130-137.
- Payton C.D., Scarisbrick D.A., Sikotra S., Flower A.J.E., "Vaccination against hepatitis B: comparison of intradermal and intramuscular administration of plasma derived and recombinant vaccines," *In: Epidemiol Infect*, **35**(1993)177-180.
- Padula S.J., Pollard M.K., Lingenheld E.G., Clark R.B., "Maintenance of antigen specificity by human interleukin-2-dependent T cell lines. Use of antigen-presenting cells and OKT3 antibody in the absence of antigen," *J Clin. Invest.*, (3),**75**(1985)788-797.
- Pasquetto V., Guidotti L.G., Kakimi K., Tsuji M., Chisari F.V., "Host-virus interactions during malaria infection in hepatitis B virus transgenic mice," *J Exp. Med.*, **192**(2000)529-536.
- Peek L.J., Middaugh C.R., Berkland C., "Nanotechnology in vaccine delivery." *Adv Drug Deliv. Rev.*, **60**(2008)915-928.
- Penna A., Artini M., Cavalli A., Levrero M., Bertoletti A., Pilli M., Chisari F.V., Rehermann B., Del Prete G., Fiaccadori F., Ferrari C., "Long-lasting memory T cell responses following self-limited acute hepatitis B," *J Clin. Invest.*, (5),**98**(1996)1185-1194.

Penna A., Chisari F.V., Bertolotti A., Missale G., Fowler P., Giuberti T., Fiaccadori F., Ferrari C., “Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid Antigen,” *J Exp. Med.*, **174**(1991)1565–1570.

Piratvisuth T., “Optimal management of HBV infection during pregnancy,” *Liver Int.*, (1),**33**(2013)188–194.

Plank C., Zauner W., Wagner E., “Application of membrane-active peptides for drug and gene delivery across cellular membranes,” *Adv. Drug Del. Rev.*, **34**(1998)21-35.

Probst C.E., Zrazhevskiy P., Bagalkot V., Gao X., “Quantum dots as a platform for nanoparticle drug delivery vehicle design,” *Adv. Drug Del. Rev.*, (5),**65**(2013)703-718.

Quasdorff M., Hosel M., Odenthal M., Zedler U., Bohne F., Gripon P., Dienes H.P., Drebber P., Stippel D., Goeser T., Protzer U., “A concerted action of HNF4alpha and HNF1alpha links hepatitis B virus replication to hepatocyte differentiation” *Cell Microbiol.*, **10**(2008)1478-1490.

Raghuvanshi R.S., Katare Y.K., Lalwani K., Ali M.M., Singh O., Panda A.K., “Improved immune response from biodegradable polymer particles entrapping tetanus toxoid by use of different immunization protocol and adjuvants,” *Int. J Pharm.*, **245**(2002)109–121.

Raney A.K., Kline E.F., Tang H., McLachlan A., “Nuclear covalently closed circular viral genomic DNA in the liver of hepatocyte nuclear factor 1 $\alpha$ -null hepatitis B virus transgenic mice,” *J. Virol.*, **75**(2001)2900-2911.

Reddy S.T., Swartz M.A., Hubbell J.A., “Targeting dendritic cells with biomaterials: developing the next generation of vaccines,” *Trends Immunol.*, **27**(2006)573–579.

Rehermann B., Fowler P., Sidney J., Person J., Redeker A., Brown M., Moss B., Sette A., Chisari F.V., “The cytotoxic T lymphocyte response to multiple hepatitis B virus

polymerase epitopes during and after acute viral hepatitis,” *J Exp. Med.*, **181**(1995)1047–1458.

Rehermann B. and Nascimbeni M., “Immunology of hepatitis B virus and hepatitis C virus infection,” *Nat. Rev. Immunol.*, (3),**5**(2005)215-229.

Roldao A., Mellado M.CM., Castilho L.R., Carrondo M.J., Alves P.M., “Virus-like particles in vaccine development,” *Expert Rev. Vaccines*, **9**(2010)1149-1176.

Rock K.L. and Shen L., “Cross-presentation: underlying mechanisms and role in immune surveillance,” *Immunol. Rev.*, **207**(2005)166-183.

Rothen-Rutishauser B.M., Schurch S., Haenni B, Kapp N., Gehr P., “Interaction of fine particles and nanoparticles with red blood cells visualized with advanced microscopic techniques,” *Environ. Sci. Technol.*, **40**(2006)4353-4359.

Saikia N., Talukdar R., Mazumder S., Khanna S., Tandon R., “Management of patients with HBeAg-negative chronic hepatitis B,” *J Postgrad Med.*, (975),**83**(2007)32–39.

Samuel C.E., “Antiviral actions of interferon. Interferon-regulated cellular proteins and their surprisingly selective antiviral activities,” *Virology*, **183**(1991)1-11.

Savina A. and Amigorena S., “Phagocytosis and antigen presentation in dendritic cells.” *Immunol. Rev.*, **219**(2007)143-156.

Scaglione S.L. and Lok A.S., “Effectiveness of hepatitis B treatment in clinical practice,” *Gastroenterology*, **142**(2012)1360-1368.

Schwartz R.H., “T cell anergy,” *Annu. Rev. Immunol.*, **21**(2003)305-334.

Scott N.R., “Nanoscience in veterinary medicine,” *Vet. Res. Commun.*, **31**(2007)139-144.

Scott N.R., "Nanotechnology and animal health," *Rev. Sci. Tech.*, (1),**24**(2005)425-432.

Seeff L.B., Beebe G.W., Hoofnagle J.H., Norman J.E., Buskell-Bales Z., Waggoner L.G., Kaplowitz N., Koff R.S., Petrini J.L., Schiff E.R., "A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States Army," *Nat. Engl. J Med.*, **316**(1987)965–970.

Seegar C., Mason W.S., "Hepatitis B Virus Biology," *Microbiol. mol. Biol. Rev.*, **64**(2000)51-68.

Segall H., Lubin I., Marcus H., Canaan A., Reisner A., "Generation of primary antigen-specific human cytotoxic T lymphocytes in human/mouse radiation chimera," *Blood*, **88**(1996)721-730.

Semmling M., Kreft O., Javier A., Sukhorukov G.B., Kas J., Parak W.J., "A novel flow-cytometry-based assay for cellular uptake studies of polyelectrolyte microcapsules" *Small*, **4**(2008)1763-1768.

Seong S.Y. and Matzinger P., "Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses," *Nat rev. Immunol.*, **4**(2004)469-478.

Service R.F., "Nanotechnology: can high-speed tests sort out which nanomaterials are safe?" *Science*, **321**(2008)1036-1037.

Sha L., Qin Q.S., WeiLin M., Yu C., "Serum immunoglobulin A (IgA) level is a potential biomarker indicating cirrhosis during chronic hepatitis B infection," *Gastroenterol. Res. Pract.*, **5**(2016)1-6.

Shang L., Nienhaus K., Jiang X., Yang L., Landfester K., Mailänder V., Simmet T., Nienhaus G.U., "Nanoparticle interactions with live cells: Quantitative fluorescence microscopy of nanoparticle size effects," *Beilstein. J Nanotechnol.*, **5**(2014)2388–2397.

Sharma S., Mukkur T.K., Benson H.A., Chen Y., “Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems,” *J Pharm. Sci.*, **98**(2009)812–893.

Shokrgozar M.A. and Shokri F., “Subtype specificity of anti-HBs antibodies produced by human B-cell lines isolated from normal individuals vaccinated with recombinant hepatitis B vaccine,” *Vaccine*, (17),**20**(2002)2215-2220.

Shrivastava V. and Jain U.K., “A validated RP-HPLC method for estimation of hepatitis B surface antigen (HBsAg) in bulk preparation,” *Orient. J Chem.*, (3),**25**(2009)763-765.

Sekhon B.S. and Saluja V., “Nanovaccines-an overview” *Int. J Pharm. Frontier Res.*, (1),**1**(2011)101-109.

Shai Y., “Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by  $\alpha$ -helical antimicrobial and cell non-selective membrane-lytic peptides,” *Biochim. Biophys. Acta*, **1462**(1999)55-70.

Shaw F.E., Guess H.A., Roets J.M., Mohr F.E., Coleman P.J., Mandel E.J., Roehm R.R., Talley W.S., Hadler S.C., “Effect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccination,” *Vaccine*, (5),**7**(1989)425-430.

Shen H., Ackerman A.L., Cody V., Giodini A., Hinson E.R., Cresswell P., Edelson R.L., Saltzman W.M., Hanlon D.J., “Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles,” *Immunology*, **117**(2006)78–88.

Shih J.Y., Yuai A., Jeremy J.W., Chen J.J., Yang P., “Tumor-associated macrophage: its role in cancer invasion and metastasis,” *J Can. Mol.*, (3),**2**(2006)101-106.

Shi Z., Yang Y., Wang H., Ma L., Schreiber A., Li X., Sun W., Zhao X., Yang X., Zhang L., Lu W., Teng J., An Y., “Breast feeding of new borns by mothers carrying

Hepatitis B Virus.: A meta-analysis and systematic Review,” *Arch. Pediatr. Adolesc. Med.*, (9),**165**(2011)837-846.

Singh M., Li X.M., McGee J.P., Zamb T., Koff W., Wang C.Y., O'Hagan D.T., “Controlled release microparticles as a single dose hepatitis B vaccine: evaluation of immunogenicity in mice,” *Vaccine*, **15**(1997)475-481.

Singh M. and O'Hagan D.T., “Recent advances in vaccine adjuvants,” *Pharm. Res.*, **19**(2002)715–772.

Singhvi G. and Singh M., “Review: In- vitro Drug Release Characterization Models,” *Int. J Pharm. Sci. Res.*, **2**(2011)77-84.

Slutter B., Hagenaars N., Jiskoot W., “Rational design of nasal vaccines,” *J. Drug Target*, **16**(2008)1-17.

Sommer G., Günther S., Sterneck M., Otto S., Will S., “A New Class of Defective Hepatitis B Virus Genomes with an Internal Poly(dA) Sequence,” *Virology*, (2),**239**(1997)402-412.

Song X., Zhao Y., Hou S., Xu F., Zhao R., “Dual agents loaded PLGA nanoparticles: systematic study of particle size and drug entrapment efficiency,” *Eur. J Pharm. Biopharm.*, **69**(2008)445-453.

Sprent J., Zhang X., Sun S., Tough D., “T cell proliferation in vivo and the role of cytokines,” *J Royal Society*, **355**(2000)317-322.

Standley S.M., Kwon T.J., Murthy N., Kunisawa J., Shastri N., Guillaudeu S.J., Lau L., Fréchet J.M.J., “Acid-degradable particles for protein-based vaccines: Enhanced survival rate for tumor-challenged mice using ovalbumin model” *Bioconjug. Chem.*, **15**(2004)1281-1288.



Steinman R.M. and Banchereau J., "Taking dendritic cells into medicine," *Nature*, **449**(2007)419-426.

Storni T., Kundig T.M., Senti G., Johansen P., "Immunity in response to particulate antigen delivery systems," *Adv. Drug Deliv. Rev.*, **57**(2005)333–355.

Sylvan S.P. and Hellstrom U.B., "HBsAg-induced interferon-gamma secretion in T cells from asymptomatic HBsAg carriers and HB-immune donors in vitro," *Immunology*, **70**(1990)197-202.

Takeda K., Kaisho T., Akira S., "Toll-like receptors," *Annu. Rev. Immunol.*, **21**(2003)335-376.

Thimme R., Wieland S., Steiger C., Ghayeb J., Reimann K.A., Purcell R.H., Chisari F.V., "CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection," *J Virol.*, **77**(2003)68–76.

Tissot A.C., Maurer P., Nussberger J., Sabat R., Pfister T., Ignatenko S., Volk H.D., Stocker H., Müller P., Jennings G.T., Wagner F., Bachmann M.F., "Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomized, placebo-controlled phase IIa study," *The Lancet*, **371**(2008)821-827.

Tough D.F. and Sprent J., "Turnover of native and memory phenotype T cells," *J Exp. Med.*, **179**(1994)1127-1135.

Trachtenberg E., Vinson M., Hayes E., Hsu Y.M., Houtchens K., Erlich H., Klitz W., Hsia Y., Hollenbach J., "HLA class I (A, B, C) and class II (DRB1, DQA1, DQB1, DPB1) alleles and haplotypes in the Han from southern China" *Tissue Antigens*, (6), **70**(2007)455-463.

Treuel L., Jiang X., Nienhaus G.U., "New views on cellular uptake and trafficking of manufactured nanoparticles," *J. Royal Soc. Interface*, **10**(2013)1-14.

Tsutsui H., Mizoguchi Y., Morisawa S., “There is no correlation between function and lymphokine production of HBs-antigen-specific human CD4(1)-cloned T cells,” *Scand. J Immunol.*, **34**(1991)433-444.

Van Vlerken L.E., Vyas T.K., Amiji M.M., “Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery,” *Pharm. Res.*, **24**(2007)1405-1414.

Verma A., Uzun O., Hu Y., Han H.S., Watson N., Chen S., Irvine D.J., Stellacci F., “Surface-structure regulated cell-membrane penetration by monolayer protected nanoparticles,” *Nat. Mater.*, **7**(2008)588-595.

Vyas J.M., Veen V.D., Ploegh H.L., “The known unknowns of antigen processing and presentation.” *Nat. Rev. Immunol.*, **8**(2008)607-618.

Wahl M. and Hermodsson S., “Intradermal, subcutaneous or intramuscular administration of hepatitis B vaccine: side effects and antibody response,” *Scand. J Infect Dis.*, (6),**19**(1987)617-621.

Walter E., Keist R., Niederost B., Pult I., Blum H.E., “Hepatitis B virus infection of tupaia hepatocytes *in vitro* and *in vivo*,” *Hepatology*, **24**(1996)1-5.

Wang L., Lin S.J., Tsai J.H., Tsai C.H., Tsai C.C., Yang C.C., “Anti-hepatitis B surface antigen IgG1 subclass is predominant in individuals who have recovered from hepatitis B virus infection, chronic carriers, and vaccines,” *Med. Microbiol. Immunol.*, (1),**194**(2005)33-38.

Wang T., Bai J., Jiang X., Nienhaus G.U., “Cellular uptake of nanoparticles by membrane penetration: a study combining confocal microscopy with FTIR spectroelectrochemistry,” *ACS Nano*, **6**(2012)1251-1259.

Wistrom J., Ahlm C., Lundberg S., Settergren B., Tarnvik A., “Booster vaccination with recombinant hepatitis B vaccine four years after priming with one single dose,” *Vaccine*, (17),**17**(1999)2162-2165.

Wong D.K., Cheung A.M., O’Rourke K., Naylor C.D., Detsky A.S., Heathcote J., “Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B,” *A meta-analysis. Ann. Intern. Med.*, **119**(1993)312-323.

World Health Organization. Hepatitis B Factsheet No. 204 (revised August 2008). Geneva: World Health Organization; 2008.

Yang N.J. and Hinner M.J., “Getting Across the Cell Membrane: An Overview for Small Molecules, Peptides, and Proteins,” *Methods Mol Biol.*, **1266**(2015)29-53.

Yant S.R., Meuse L., Chiu W., Izsvak Z., Kay M.A., “Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system,” *Nat. Genet.*, **25**(2000)35-41.

Yao X., Zheng B., Zhou J., Xu D.Z., Zhao K., Sun S.H., Yuan Z.H., Wen Y.M., “Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients,” *Vaccine*, (10),**25**(2007)1771-1779.

Yen T.S.B., *The Molecular Biology of Hepatitis B Virus*, In *Hepatitis Viruses*, 2nd edition, Kluwer Academic Publishers, Norwell, Massachusetts, 2010,51-79.

Yessine M.A. and Leroux J.C., “Membrane-destabilizing polyanions: interaction with lipid bilayers and endosomal escape of bio-macromolecules,” *Adv. Drug Deliv. Rev.*, **56**(2004)999-1021.

Zambaux M.F., Bonneaux F., Gref R., Maincent P., Dellacherie E., Alonso M.J., “Influence of experimental parameters on the characteristics of poly(lactic acid)

nanoparticles prepared by a double emulsion method,” *J Controlled Release*, **50**(1998)31-40.

Zhang S.L., Yue Y.F., Bai G.Q., Shi L., Jiang H., “Mechanism of intrauterine infection of hepatitis B virus,” *World J Gastroenterol.*, (3),**10**(2004)437-438.

Zhang T., Stilwell J.L., Gerion D., Lianghao D., Elboudwarej O., Cooke P.A., Gray J.W., Alivisatos P.A., Chen F.F., “Cellular effect of high doses of silica-coated quantum dot profiled with high throughput gene expression analysis and high content cellomics measurements,” *Nano Lett.*, **6**(2006)800-808.

Zhao Z. and Leong K.W., “Controlled delivery of antigens and adjuvants in vaccine development,” *J Pharm. Sci.*, **85**(1996)1261–1270.

Zhou Y.Z., Alany R.G., Chuang V., Wen J., “Optimization of PLGA nanoparticles formulation containing L-DOPA by applying the central composite design,” *Drug Dev. Ind. Pharm.*, (2),**39**(2013)321-330.

Zolnik B.S., González-Fernandez A., Sadrieh N., Dobrovolskaia M.A, “Nanoparticles and the immune system,” *Endocrinology*, (2),**151**(2010)458-465.

Zuckerman J.N., Cockcroft A., Zuckerman A.J., “Site of injection for vaccination,” *British Med. Journal*, (6862),**305**(1992)1158-1165.

-----